Envision Pharma Group presents original research at ISPOR

Event icon


May 19, 2017

Envision Pharma Group presents original research at ISPOR in Boston, May 20–24

Envision Pharma Group will be presenting original research at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – Sheraton Boston Hotel and the John B. Hynes Veterans Memorial Convention Center, Boston, MA, USA, May 20−24, 2017.

Members of Envision’s Market Access Solutions team and their co-authors present new insights on the important issue of biosimilar uptake and use in the USA. Both presentations will take place in Research Poster Presentations – Session II on Monday, May 22nd (3:45-7:45pm), with an Author Discussion Hour between 6:45pm and 7:45pm.

Envision’s Karen Smoyer, PhD and Bríain Ó Hartaigh, PhD will be presenting research on the “Uptake of the First US Biosimilar: Filgrastim-sndz Utilization Observed in a Medical Transcription Database of Patient Office Visits”.

Envision’s Karen Smoyer, PhD and Trevor Fitzpatrick, CMPP will be presenting research conducted in collaboration with Cardinal Health on the “Initial Uptake and Utilization Patterns of Filgrastim-sndz, the First US Biosimilar”.

The theme of this year’s meeting is “Evidence and Value in a Time of Social and Policy Change” and full details of the agenda can be found here or via the meeting App for iOS or ANDROID devices.

Follow events in Boston on Twitter using #ISPORBoston

To arrange a personal meeting with representatives from the newly combined Envision and Curo team, where we'll be building bridges between Evidence and Value with our range of Market Access and HEOR platforms and other technology solutions, visit us in Boston at Booth 1022 or contact Envision’s Trevor Fitzpatrick or Karen Smoyer, or Curo’s Chris O’Neill.

Envision Pharma Group logo